Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

By The Northwire Desk — AI Analysis Apr 13, 2026 · 17:00 XRTX · 3.42 XORTX Therapeutics Inc.
XRTX · Price

Executive Summary

  • XORTX Therapeutics Inc. has closed the acquisition of the VB4-P5 kidney anti-fibrotic asset from Vectus Biosystems Limited.
  • The acquired program consists of a novel new chemical entity (VB4-P5) designed to inhibit and potentially reverse kidney fibrosis in both rare and prevalent forms of chronic kidney disease (CKD).
  • The total acquisition price is US$3.0 million, settled via the issuance of common shares and pre-funded warrants.

Key Details

  • Asset Acquired: VB4-P5 Renal Anti-Fibrotic Therapeutic Program, including:
    • Novel new chemical entity (VB4-P5).
    • Associated intellectual property (composition-of-matter and method-of-use claims across 30+ global jurisdictions).
    • Regulatory documentation and manufacturing data.
  • Development Stage: Pre-IND (Investigational New Drug).
  • Target Indications: Mid-late stage chronic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), and lupus nephritis.
  • Transaction Consideration: Total aggregate price of US$3.0 million, comprised of:
    • Common Shares: 154,544 shares at a deemed issue price of US$3.5432 (CAD$4.9668).
    • Pre-funded Warrants: 692,150 warrants at a deemed issue price of US$3.5431 (CAD$4.9667).
  • Warrant Terms:
    • Exercise Price: US$0.0001.
    • Expiration Date: April 13, 2031.
    • Ownership Cap: Vectus is prohibited from exercising warrants if the result would lead to ownership exceeding 9.99% of XORTX's issued and outstanding common shares.
  • Market Context: The company estimates the addressable market for this treatment exceeds 10 million individuals, noting that CKD affects approximately 14% of adults globally.

Notable Quotes

  • Dr. Allen Davidoff, CEO of XORTX: “We are pleased to have finalized the Acquisition of the VB4-P5 program for kidney disease. This program is directly aligned with our strategic focus on developing innovative therapies to treat individuals with progressive kidney disease and broadens our pipeline with a new technological direction.”
Read the original news release →

More from XORTX Therapeutics Inc.

Jun 15, 2026 · 07:00

Micro-Cap Biotech Secures FDA Pathway Clarity and Capital, but Execution Risk Remains High

Regulatory May 19, 2026 · 07:00

XORTX closes deep-discount offering with half the proceeds going to investor relations, signaling potential desperation and further dilution ahead.

Financings May 18, 2026 · 11:20

XORTX closes fire‑sale offering at a 38% discount, shareholders left to weather prolonged cash drought and dilutive pipeline.

Financings May 14, 2026 · 07:00

XORTX’s Deep-Discount Rescue Financing Signals Desperation as Biotech’s Cash Burn Leaves Investors Underwater

Financings Mar 24, 2026 · 20:42

XORTX Therapeutics shareholders approve 1:10 rollback

Other Mar 18, 2026 · 16:47

XORTX Therapeutics proposes three director nominees

Financings